I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Canada

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Haematology Acute Myeloid Leukemia

Acute Myeloid Leukemia

What's new

Sign up or login to unlock the full suite of MEDICALLY features
Dec 7 / Roche and Genentech
Incorporating Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) into Dose Review in a Phase I Clinical Trial
Adverse event information from the Common Terminology Criteria for Adverse Events (CTCAE) and the Patient-Reported Outcomes version of the CTCAE was incorporated into a dose review report from a Phase I trial of patients with relapsed/refractory acute myeloid leukemia. Results from the final dose review report in a cohort of four patients, including feedback on the report, are presented.
Haematology Oncology Acute Myeloid Leukaemia ASH-2024

Sign up or login to unlock the full suite of MEDICALLY features
Jul 4 / Roche and Genentech
Real-World Treatment Experience of Venetoclax in Combination with Hypomethylating Agents in Patients with Newly Diagnosed Acute Myeloid Leukemia: Updated Experience from a Predominantly Community Setting in the US
A retrospective cohort study using the Flatiron Health electronic health record-derived, nationwide, de-identified database to better understand the real-world treatment experience of Ven+HMA in routine clinical care pre- and post-VIALE-A in patients with newly diagnosed acute myeloid leukemia.
Haematology Oncology Acute Myeloid Leukaemia ASH-2022

Sign up or login to unlock the full suite of MEDICALLY features
Jul 7 / Roche and Genentech
Clinical Evaluation of Somatic Genomic Alteration Annotation for Hematological Malignancies using NAVIFY® Tertiary Analysis Software
The NAVIFY® Mutation Profiler is a CE-marked, cloud-based tertiary analysis software that provides curation, annotation, and reporting of somatic genomic alterations and biomarker signatures identified by NGS (next-generation sequencing). This poster shows the results of a clinical evaluation study validating the accuracy and reproducibility of the NMP software and curation process across a panel of hematologic malignancies.
Haematology Acute Lymphocytic Leukemia Leukaemia & Lymphoma Diffuse Large B-Cell Lymphoma Acute Myeloid Leukaemia Chronic Lymphocytic Leukaemia Follicular Lymphoma Multiple Myeloma AACR-2022

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.